EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biocept's enterprise value is $4.96 Mil.
Biocept's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $1.36 Mil. Therefore, Biocept's EV-to-Revenue for today is 3.66.
The historical rank and industry rank for Biocept's EV-to-Revenue or its related term are showing as below:
BIOCQ'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1.54 Med: 3.66 Max: 378.21
Current: 3.66
During the past 12 years, the highest EV-to-Revenue of Biocept was 378.21. The lowest was -1.54. And the median was 3.66.
BIOCQ's EV-to-Revenue is ranked worse than 58.15% of 227
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.02
vs BIOCQ: 3.66
As of today (2024-04-27), Biocept's stock price is $0.0001.
Biocept's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $1.89. Therefore, Biocept's PS Ratio for today is 0.00.
Biocept EV-to-Revenue Historical Data
The historical data trend for Biocept's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biocept's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocept's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Biocept's EV-to-Revenue falls into.
Biocept's current Enterprise Value is $4.96 Mil.
Biocept's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocept's share price for today is $0.0001.
Biocept's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocept EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Biocept's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOCQ has been successfully added to your 